Sanofi India rose 1.68% to Rs 7,097 after the company's standalone net profit surged 63.39% to Rs 238.40 crore on a 2.49% fall in revenue from operations to Rs 707 crore in Q1 March 2022 over Q1 March 2021.
Consolidated profit before tax (PBT) jumped 67.11% to Rs 325.70 crore in Q1 March 2022 as against Rs 194.90 crore in Q1 March 2021. Total expenses decreased by 5.87% to Rs 523.80 crore in Q1 March 2022 as compared to Rs 556.5 crore in Q1 March 2021.
Sanofi India is one of the entities through which Sanofi operates in India. It offers a wide array of medicines for therapy areas such as diabetes, cardiology, thrombosis, central nervous system and anti-histamines. The products manufactured by the company are distributed in India and exported to many developed as well as developing countries.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU